VICTORIA, BC, Sept. 28, 2020 /CNW/ - IMMUNOPRECISE
ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF)
(FSE:TQB2), a leader in full-service, therapeutic antibody
discovery and development, today announced that Dr. Jennifer Bath, CEO of IPA, is scheduled to
appear today as a guest on Bloomberg Technology with host
Emily Chang at approximately
5:10 p.m. ET.
Dr. Bath will discuss the Company's comprehensive anti-COVID-19
programs - its Polytope™ Therapy and Vaccines strategies. IPA
believes it has launched the most comprehensive and diverse global
antibody cocktail program in the world, which, unlike current
approaches, is designed to provide durable, long-lasting protection
for the entire population and potential mutations.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a
global technology platform company with end-to-end solutions
empowering companies to discover and develop therapies against any
disease. The Company's experience and cutting-edge technologies
enable unparalleled support of its partners in their quest to bring
innovative treatments to the clinic. ImmunoPrecise's full-service
capabilities dramatically reduce the time required for, and the
inherent risk associated with, conventional multi-vendor product
development. For further information,
visit www.immunoprecise.com or contact
solutions@immunoprecise.com.
Forward Looking Information
This news release
contains statements that, to the extent they are not recitations of
historical fact, may constitute "forward-looking statements" within
the meaning of applicable Canadian securities laws. The Company
uses words such as "may", "would", "could", "will", "likely",
"expect", "believe", "intend", "should" and similar expressions to
identify forward-looking statements and include the Company's
beliefs with respect to the potential for its antibodies to be
further developed or approved to treat COVID-19 (or SARS-CoV-2)
or to complete any transactions with respect to those
antibodies. Any such forward-looking statements are based on
assumptions and analyses made by ImmunoPrecise in light of its
experience and its perception of historical trends, current
conditions and expected future developments. However, whether
actual results and developments will conform to ImmunoPrecise's
expectations and predictions is subject to any number of risks,
assumptions and uncertainties. Many factors could cause
ImmunoPrecise's actual results to differ materially from those
expressed or implied by the forward-looking statements contained in
this news release. Such factors include, among other things, actual
revenues and earnings for IPA being lower than anticipated, and
those risks and uncertainties described in ImmunoPrecise's annual
management discussion and analysis for the previous quarter ended
April 30, 2020 which can be accessed
at www.sedar.com. The "forward-looking statements"
contained herein speak only as of the date of this press release
and, unless required by applicable law, ImmunoPrecise undertakes no
obligation to publicly update or revise such information, whether
as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release. SOURCE ImmunoPrecise Antibodies
View original
content:http://www.prnewswire.com/news-releases/ipa-ceo-dr-jennifer-bath-to-appear-live-today-on-bloomberg-television-301139097.html
SOURCE ImmunoPrecise Antibodies Ltd.